Why Is CRISPR THERAPEUTICS (CRSP) Stock Up Today?

CRSP stock rose 4.21% to $59.48 in morning trading as a key analyst firm reaffirmed its positive stance on the company. The move followed a report that Citizens has maintained its market outperform rating on CRISPR Therapeutics. This comes amid recent developments in the company’s gene therapy data, which appear to have reinforced confidence in the firm’s long-term prospects.

What Happened

Citizens reaffirmed its positive outlook on CRISPR Therapeutics, citing encouraging gene therapy data. The firm has maintained its price target of $80 for the stock, signaling continued belief in its potential. This update occurred alongside broader market movements that included other biotech and pharmaceutical names. The stock opened at $57.14 and quickly climbed to a session high of $59.74 shortly after 9:45 AM ET. The move followed a recent trend of elevated interest in CRISPR-related developments.

What The Data Shows

CRSP has seen a significant price increase over the past eight sessions, rising 11.6% from $47.64 to $53.16. The stock has also printed 10 fresh 52-week highs on August 25, 2026. However, the company remains unprofitable, with an EPS of -4.76 and revenue declining 64.8% year to date. The stock’s beta of 1.74 indicates it is more volatile than the broader market. Recent insider activity includes a sale by Chief Medical Officer Naimish Patel on May 29, 2026, and a total of $211K in insider sales over the past 90 days.

What To Watch

Investors should monitor coverage breadth as the stock continues to attract attention. No earnings date is provided, but ongoing analyst commentary and gene therapy developments may influence future price action.